| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Neurology (Drs. Moll and Vecht), Rheumatology (Dr. Markusse), and Pathology (Dr. Henzen-Logmans and J.J.J.M. Pijnenburg), Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Neurologic complications of both the central and peripheral nervous systems occur frequently in patients with primary Sjögren's syndrome (primary SS), but the underlying cause of these complications is unknown. We studied the presence of antineuronal antibodies in relation to neurologic complications in a consecutive series of 45 patients with primary SS. Twenty-five patients had neurologic complications: 12 patients with polyneuropathy, three with psychiatric disorders, four with carpal tunnel syndrome, seven with migraine, seven with myalgia, and four with other complications (transverse myelitis, stroke, Bell's palsy, and pyramidal signs). Ten patients had more than one neurologic complication. Eleven patients had major and 14 had minor complications according to criteria used for rating neurologic complications in patients with systemic lupus erythematosus. Antineuronal antibodies were present in six of 11 (55%) patients with major neurologic complications and in four of 34 (11%) of patients without major neurologic complications (p = 0.001). This difference could be attributed mainly to the group of patients with polyneuropathy. Three of the 10 sera of patients with positive antineuronal antibodies had antibodies reacting with a 38-kd neu-ronal protein on immunoblotting, identical to the anti-Hu antibody reactivity in paraneoplastic neurologic disease associated with small-cell lung cancer.
Address correspondence and reprint requests to Dr. Ch. J. Vecht, Dr. Daniel den Hoed Cancer Center, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands.
Supported by The Jan Dekker and Ludgardine Bouwman Fund. J.W.B. Moll is a recipient of a clinical investigator grant of The Netherlands Organization for Scientific Research (NWO).
Presented in part at the 45th annual meeting of the American Academy of Neurology, New York, NY, April 1993.
Received January 21, 1993. Accepted for publication in final form May 5, 1993.
This article has been cited by other articles:
|
|
 |
|
  F C Soliotis, C P Mavragani, and H M Moutsopoulos Central nervous system involvement in Sjogren's syndrome Ann Rheum Dis, June 1, 2004; 63(6): 616 - 620. [Full Text]
|
|
|
|
 |
|
 S. Shams'ili, J. Grefkens, B. de Leeuw, M. van den Bent, H. Hooijkaas, B. van der Holt, C. Vecht, and P. Sillevis Smitt Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients Brain, June 1, 2003; 126(6): 1409 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M J Rood, J F Haverman, S G van Duinen, F C Breedveld, J J G M Verschuuren, and T W J Huizinga CNS involvement in systemic lupus erythematosus: a case with remarkable histopathological findings Ann Rheum Dis, March 1, 2001; 60(3): 299 - 300. [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Cox and R. E. Hales CNS Sjogren's Syndrome: An Underrecognized and Underappreciated Neuropsychiatric Disorder J Neuropsychiatry Clin Neurosci, May 1, 1999; 11(2): 241 - 247. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. M. Fathallah-Shaykh Paraneoplastic Neurological Syndromes: Paraneoplastic or Neurological? Arch Neurol, February 1, 1999; 56(2): 151 - 152. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
